Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

(2016) T. Blevins et al.   DIABETES OBESITY & METABOLISM

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

(2016) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

(2016) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

(2016) S. Garg et al.   DIABETES OBESITY & METABOLISM

New insights into the pathophysiology of dyslipidemia in type 2 diabetes

(2015) Marja-Riitta Taskinen et al.   ATHEROSCLEROSIS

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

(2015) John B. Buse et al.   DIABETES CARE

Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids

(2015) Daniel F. Vatner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia

(2015) Klaus G. Parhofer   Diabetes & Metabolism Journal

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

(2014) Robert R. Henry et al.   DIABETES CARE

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

(2013) M. C. Moore et al.   DIABETES

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

(2013) V. P. Sinha et al.   DIABETES OBESITY & METABOLISM

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes

(2011) A. Chaudhuri et al.   DIABETES OBESITY & METABOLISM

Insulin effects in muscle and adipose tissue

(2011) George Dimitriadis et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Both Intestinal and Hepatic Lipoprotein Production Are Stimulated by an Acute Elevation of Plasma Free Fatty Acids in Humans

(2008) Hélène Duez et al.   CIRCULATION